April 30th 2025
The company’s intent is to establish Merck Wilmington Biotech as the future United States home for producing Keytruda for US patients.
Momenta Receives Warning Letter for Generic Copaxone
February 21st 2017In a press release, Momenta announced on Feb. 16, 2017 that Momenta/Sandoz’s fill/finish contract manufacturer, Pfizer, received a warning letter for the manufacture of the 40 mg of Glatopa (glatiramer acetate injection), Momenta’s generic version of the drug Copaxone. Pfizer said in the statement that the warning letter does not affect the production or shipment of the 20 mg version of the drug, which is already approved by FDA.
ISPE Announces Facility of the Year Awards Category Winners for 2016
February 2nd 2016The International Society for Pharmaceutical Engineering (ISPE) Facility of the Year Awards (FOYA) program announced its 2016 Category Award winners for operational excellence, sustainability, process innovation, project execution, equipment innovation, and facility integration.